New drug combo aims to boost muscle disease treatment
NCT ID NCT07284420
Summary
This study is testing whether adding a new drug called empasiprubart to an existing treatment (efgartigimod) can better control symptoms of myasthenia gravis. It will involve about 70 adults with a specific type of this muscle-weakening disease who have had only a partial improvement on the standard treatment. Researchers will compare how well the combination works versus the standard treatment alone over about a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dent Neurologic Institute - Amherst
RECRUITINGAmherst, New York, 14226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Erlanger Health System
RECRUITINGChattanooga, Tennessee, 37403, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Neuromuscular Research Institute
RECRUITINGAustin, Texas, 78756, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Profound Research LLC - Carlsbad
RECRUITINGCarlsbad, California, 92011, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Visionary Investigators Network
RECRUITINGMiami, Florida, 33176, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.